In vivo, sustained low-dose IL-2 therapy reduced cTfh cells significantly but had little effect on cTfr cells, which resulted in recovered Tfr/Tfh ratio in lupus mice and patients (118, 119). This evidence concerns the gene TFRC and systemic lupus erythematosus.